Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

References for PMC Articles for PubMed (Select 21681446)

2.

Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer.

Liang SY, Phillips KA, Wang G, Keohane C, Armstrong J, Morris WM, Haas JS.

Med Care. 2011 Jun;49(6):e1-8. doi: 10.1097/MLR.0b013e318207e87e.

3.

The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.

Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S.

Breast Cancer Res Treat. 2011 Apr;126(3):797-802. doi: 10.1007/s10549-010-1329-6. Epub 2011 Jan 1.

PMID:
21197567
4.

Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction.

Webber EM, Lin JS, Evelyn P Whitlock.

PLoS Curr. 2010 Sep 2;2. pii: RRN1177. doi: 10.1371/currents.RRN1177.

5.

Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.

Kerlikowske K, Cook AJ, Buist DS, Cummings SR, Vachon C, Vacek P, Miglioretti DL.

J Clin Oncol. 2010 Aug 20;28(24):3830-7. doi: 10.1200/JCO.2009.26.4770. Epub 2010 Jul 19.

6.

Cancer statistics, 2010.

Jemal A, Siegel R, Xu J, Ward E.

CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.

7.

Economic implications of 21-gene recurrence score assay: US multicenter experience.

Hornberger J, Lyman GH, Chien R.

J Clin Oncol. 2010 Aug 1;28(22):e382; author reply e383. doi: 10.1200/JCO.2010.28.8944. Epub 2010 May 24. No abstract available.

8.

Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.

Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI.

Oncologist. 2010;15(5):457-65. doi: 10.1634/theoncologist.2009-0275. Epub 2010 Apr 26.

9.

Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.

Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J.

Value Health. 2010 Jun-Jul;13(4):381-7. doi: 10.1111/j.1524-4733.2010.00724.x. Epub 2010 Apr 15.

PMID:
20412544
10.

Physician cost profiling--reliability and risk of misclassification.

Adams JL, Mehrotra A, Thomas JW, McGlynn EA.

N Engl J Med. 2010 Mar 18;362(11):1014-21. doi: 10.1056/NEJMsa0906323.

11.

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.

Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, Albain KS.

J Clin Oncol. 2010 Apr 1;28(10):1671-6. doi: 10.1200/JCO.2008.20.2119. Epub 2010 Jan 11.

12.

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America.

Lancet Oncol. 2010 Jan;11(1):55-65. doi: 10.1016/S1470-2045(09)70314-6. Epub 2009 Dec 10.

13.

Gene-expression signatures in breast cancer.

Sotiriou C, Pusztai L.

N Engl J Med. 2009 Feb 19;360(8):790-800. doi: 10.1056/NEJMra0801289. Review. No abstract available.

PMID:
19228622
14.

Pharmacogenomics, evidence, and the role of payers.

Deverka PA.

Public Health Genomics. 2009;12(3):149-57. doi: 10.1159/000189627. Epub 2009 Feb 10.

15.

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW Jr, Perez EA, Shulman LN, Martino S, Sparano JA.

J Clin Oncol. 2008 Sep 1;26(25):4063-71. doi: 10.1200/JCO.2007.14.4501. Epub 2008 Aug 4. Erratum in: J Clin Oncol. 2009 Jul 20;27(21):3566.

16.

Evaluation of trends in the cost of initial cancer treatment.

Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML.

J Natl Cancer Inst. 2008 Jun 18;100(12):888-97. doi: 10.1093/jnci/djn175. Epub 2008 Jun 10.

17.

Clinical application of the 70-gene profile: the MINDACT trial.

Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ.

J Clin Oncol. 2008 Feb 10;26(5):729-35. doi: 10.1200/JCO.2007.14.3222.

18.

Systematic review: gene expression profiling assays in early-stage breast cancer.

Marchionni L, Wilson RF, Wolff AC, Marinopoulos S, Parmigiani G, Bass EB, Goodman SN.

Ann Intern Med. 2008 Mar 4;148(5):358-69. Epub 2008 Feb 4. Review.

PMID:
18252678
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk